RxDoctor Payments Data

Terry Vanwormer, PA

Physician Assistant · Layton, UTNPI 1467439505

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 94 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$395
  • AbbVie$290
  • Coloplast$182
  • Sumitomo Pharma America, Inc.$173
  • 180 Medical, Inc.$161
  • Urovant Sciences Inc$121
  • plus $837 from 20 others

What the payments were for

  • Food & beverage$2,155100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 85th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$100,727
Medicare patients
394
Services billed
5,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron110$62,209
GemtesaVibegron17$15,461
Alfuzosin Hcl ErAlfuzosin Hcl418$7,693
Tamsulosin Hcl199$2,398
Cefdinir72$2,325
Doxycycline Monohydrate72$1,985
Clindamycin Hcl72$1,796
Finasteride126$1,414
Solifenacin Succinate33$1,198
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim104$1,172
Silodosin15$947
Methenamine Hippurate19$923
Ciprofloxacin Hcl49$448
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$319
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$87$62,209110 claims
Sumitomo Pharma America, Inc.Gemtesa$173$15,46117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →